(Offering notice number 11-280 dated 30th June 2011 approved by the French financial market regulator AMF)
BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty
and orphan oncology products, today announces its successful capital increase, with maintenance of
preferential subscription rights launched on July 1st, 2011, for a total of €16,64 million raised.
“We are very pleased with the success of our capital increase achieved in a market environment
turned out to be tough and unforeseeable, and we wish to thank our shareholders for their confidence
and support to the Company’s growth strategy”, comments Judith Greciet, CEO of BioAlliance
The raised funds will enable:
To finance the development program of Livatag® in the treatment of primary liver cancer,
with a phase III trial scheduled in 2012, in the wake of the significant survival data observed
in the phase II trial.
To complement the orphan products portfolio with targeted acquisitions, in addition to the
3 products already in clinical phase, in order to maximize market access opportunities while
benefiting from the Company’s know-how in the development and the registration of
« This financing will allow us to accelerate the development and market access of our most promising
projects, as well as to enlarge our “oncology orphan products” portfolio, a key asset of our future
growth”, adds Judith Greciet.
Characteristics of the issuance
As the transaction was oversubscribed, all shares from the offer (3,395,943 new ordinary shares) will
therefore be issued for a gross total amount of 16,640,120 Euros. The share capital will thus
be increased from €3,395,943 to €4,244,928.75 divided into 16,979,715 shares of €0.25 nominal
value per share.
This document may not be published, distributed or disseminated, directly or indirectly,
in the United States of America, Canada, Australia or Japan.
The settlement and delivery of the new shares will occur on August 1, 2011 and 3,395,943 new
shares will be listed on NYSE Euronext Paris on August 2, 2011 on the same listing line as the existing
shares of the company (FR0010095596).
Partner of the transaction
BioAlliance Pharma thanks its advisory partners in this capital increase transaction, and especially:
: Advisor, Order centralizer